
Apple iPhone 17 Release Date: New Leak Reveals Latest Key Data
Last month, I assessed exactly when the next iPhone series, would go on sale. Now, Mark Gurman from Bloomberg has had his say. Happily, it's along the same lines, so perhaps we can begin to be confident when the iPhone will land. Read on for the exact schedule in every detail.
Apple iPhone 16: when will the iPhone 17 go on sale, exactly?
In the latest edition of his Power On newsletter, Gurman seeks to answer the question: 'When will Apple hold its iPhone 17 launch event?'
Apple iPhone 17: Date, Time And Place Of The Keynote
Although he went into much less detail than my report (and I admit it, brevity is the soul of wit), he lighted on similar dates.
'The company usually unveils its new iPhones the week after Labor Day. If that holds — and there's no reason to believe it won't — you can pencil in the keynote for the week of Sept. 8,' he began.
This continues to make sense to me: the week before would be when the large-scale electronics trade show IFA takes place in Berlin and it's already thought that there will be some big announcements there. Apple won't want to share the spotlight with the myriad other brands popping up in Berlin.
'In the past, Apple has typically favored Tuesdays, but there have been some exceptions in recent years,' Gurman goes on. He's referring to the fact that last year's event, against most people's expectations, including his, was held on a Monday. I'm quietly delighted that I did report the right date in advance. Forgive me a moment of conceited humility, please.
'So it could be that Monday (the 8th), though I suspect the 9th or 10th is probably more likely. Apple never holds events on Fridays, so you can rule out the 12th, and it has avoided launching new products on Sept. 11,' Gurman concludes.
This is the new information here. I had only briefly considered the Monday, but Gurman is giving it more credence. However, we both think that Tuesday 9 or Wednesday 10 are more likely. As I said before, my money is on the keynote happening on Tuesday, Sept. 9 at the absolutely regular time that it always does, that is, 10 a.m. Pacific. And the location will, I'm sure, be in the Steve Jobs Theater in Cupertino.
Apple iPhone 17 Pre-Orders
Assuming that date is right, then other parts of the puzzle fall into place. First of all, pre-orders are almost certain to open on the following Friday, which is Sept. 12. Usually, this means you can log on to buy at 1 p.m. local time, wherever you are, on that day.
In the past, customers can jump the line the night before pre-orders open — Thursday, Sept. 11 in this case — so they can save the color, storage level and model of iPhone in their online shopping bag and complete the purchase when pre-orders open the following day.
Apple iPhone 17 Release Date
Gurman only talks about the keynote, but when will the onsale date be?
I still think the iPhone 17 series will go on sale on Friday, Sept.19.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
18 minutes ago
- Yahoo
Kezar Life Sciences Announces FDA Has Lifted Partial Clinical Hold on PORTOLA Phase 2a Trial Evaluating Zetomipzomib for the Treatment of Patients with Autoimmune Hepatitis
SOUTH SAN FRANCISCO, Calif., July 15, 2025--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Division of Hepatology and Nutrition of the U.S. Food and Drug Administration (FDA) has lifted the partial clinical hold on the completed PORTOLA Phase 2a clinical trial evaluating zetomipzomib, a first-in-class selective immunoproteasome inhibitor, in patients with autoimmune hepatitis (AIH). "We are pleased that the FDA has lifted the partial clinical hold on zetomipzomib in AIH after their review of our comprehensive safety assessment of the zetomipzomib program," said Chris Kirk, PhD, CEO and co-founder of Kezar. "We continue to believe that zetomipzomib has the potential to positively transform the lives of patients living with AIH. We look forward to engaging with the FDA to align on the design of the next clinical trial of zetomipzomib in AIH." Although Kezar has suspended development of zetomipzomib in lupus nephritis (LN) to focus on AIH, the company met with the Independent Data Monitoring Committee (IDMC) for the previously terminated PALIZADE clinical trial to review the safety profile of zetomipzomib. The IDMC has provided Kezar with recommendations for conducting future clinical trials in LN. Based on this feedback and internal analysis of safety data across all clinical studies involving zetomipzomib, Kezar plans to respond to the FDA Division of Rheumatology and Transplant Medicine with a request to lift the clinical hold on zetomipzomib in LN. About Zetomipzomib Zetomipzomib is a novel, first-in-class, selective immunoproteasome inhibitor with broad therapeutic potential across multiple autoimmune diseases. Preclinical research demonstrates that selective immunoproteasome inhibition results in a broad anti-inflammatory response in animal models of several autoimmune diseases, while avoiding immunosuppression. Data generated from completed clinical trials provide evidence that zetomipzomib exhibits a favorable safety and tolerability profile for development in severe, chronic autoimmune diseases. About Autoimmune Hepatitis Autoimmune hepatitis (AIH) is a rare chronic disease in which the immune system attacks the liver and causes inflammation and tissue damage, severely impacting patients' physical health and quality of life. Lifelong maintenance therapy is required to avoid relapse and burdensome adverse effects. If left untreated, AIH can lead to cirrhosis, liver failure and hepatocellular carcinoma. In the United States, AIH affects approximately 100,000 individuals, with incidence rates increasing. The cause of this condition remains unclear, with females affected four times as often as males. Currently, standard of care treatment for AIH is chronic, immunosuppressive treatment with corticosteroids that frequently cause life-altering side effects, including diabetes, osteoporotic fractures and cataracts. There is a significant need for treatment regimens that reduce or remove the need for chronic immunosuppression from use of corticosteroids. About Kezar Life Sciences Kezar Life Sciences is a clinical-stage biopharmaceutical company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases. Zetomipzomib, a selective immunoproteasome inhibitor, is currently being evaluated for autoimmune hepatitis. This product candidate also has the potential to address multiple chronic immune-mediated diseases. For more information, visit and follow us on LinkedIn, Facebook, Twitter and Instagram. Cautionary Note on Forward-looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "can," "should," "expect," "believe," "potential," "anticipate" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Kezar's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties that could cause Kezar's clinical development programs, future results or performance to differ materially from those expressed or implied by the forward-looking statements. Forward-looking statements contained in this press release include, but are not limited to, statements about the timing and outcome of regulatory submissions and interactions with the FDA, EMA or any other regulatory agencies with respect to zetomipzomib or Kezar's clinical trials, the initiation of an additional clinical trial of zetomipzomib in AIH, and expectations regarding the removal of the clinical hold of zetomipzomib in LN, and the likelihood of obtaining regulatory approval of zetomipzomib. Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during clinical studies, difficulties enrolling and conducting our clinical trials, changes in expected or existing competition, changes in the regulatory environment, the uncertainties and timing of the regulatory approval process, and unexpected litigation or other disputes. Other factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Kezar's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Kezar assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. View source version on Contacts Investor and Media Contact:Gitanjali JainSenior Vice President, Investor Relations and External AffairsKezar Life Sciences, Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
21 minutes ago
- Yahoo
Nvidia, AMD Stocks Rise on US-China Reversal
Shares of Nvidia and Advanced Micro Devices rose as the companies prepared to resume sales of some AI products to China. Bloomberg's Mike Shepard discusses the US policy reversal with Ed Ludlow on "Bloomberg Tech."


Washington Post
23 minutes ago
- Washington Post
Google partners with Youngkin and offers AI training courses to Virginia job seekers
RESTON, Va. — Republican Gov. Glenn Youngkin announced on Tuesday that Google will partner with his administration to provide free and low-cost artificial intelligence certification courses to Virginians as part of his office's ongoing effort to connect citizens to new jobs amid changes to the state's economy. The partnership, which he has described as an AI career launchpad, will provide Google-sponsored AI training courses for up to 10,000 Virginians at any given time, officials said at Google's office in the northern part of the state.